Cancer Immunotherapy Through Tumor Cell Vaccines

Cancer immunotherapy through tumour cell vaccines harnesses the adaptive immune system by presenting tumour antigens in a controlled vaccine formulation. Whole tumour cells, tumour lysates or engineered tumour cells serve as a source of both known and unknown antigens, ensuring broad epitope coverage irrespective of HLA type. These vaccines are often combined with adjuvants such as cytokines (e.g. GM-CSF) or immunomodulatory agents to enhance dendritic cell activation and T-cell priming. By providing an array of tumour-associated antigens including neoantigens, cell-based vaccines aim to stimulate robust CD4+ helper and CD8+ cytotoxic T-cell responses, overcoming central and peripheral tolerance mechanisms. Strategies have evolved from simple irradiated allogeneic cells to sophisticated platforms incorporating antigen presentation modulators, checkpoint blockade antibodies and genetic alterations to boost immunogenicity. Preclinical models have demonstrated that combination approaches—such as pairing vaccines with inhibitors of immunosuppressive pathways (e.g. PI3Kγ inhibition to limit myeloid-derived suppressor cells)—can yield potent antitumour activity. Clinically, cell-based vaccines have shown promising safety profiles and preliminary efficacy in melanoma, lung cancer and other solid tumours. Ongoing work seeks to refine antigen delivery, enhance specificity and integrate these vaccines with standard-of-care therapies to achieve durable tumour control and long-term immunity.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Cancer Immunotherapy Through Tumor Cell Vaccines publication trend

The graph below shows the total number of articles in cancer immunotherapy through tumor cell vaccines across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour cell vaccine: A formulation of whole or engineered tumour cells used to present a broad range of tumour antigens and stimulate adaptive immune responses.

Dendritic cell: A professional antigen-presenting cell that processes and presents antigens to T cells, initiating adaptive immunity.

Immune checkpoint inhibitor: A monoclonal antibody that blocks regulatory pathways (e.g. PD-1, CTLA-4) to enhance T-cell mediated antitumour activity.

Myeloid-derived suppressor cell (MDSC): A heterogeneous population of immature myeloid cells that suppress T-cell responses and promote tumour immune evasion.

References

1. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. Journal of Experimental & Clinical Cancer Research (2024).
2. Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial. Clinical Cancer Research (2023).
3. Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Frontiers in Immunology (2017).
4. Whole Tumor Antigen Vaccines: Where Are We?. Vaccines (2015).
5. Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLOS ONE (2015).